[Atrial fibrillation and anticoagulation in hemodialysis patients: A complex decision]

Area of Science:

• Nephrology and Cardiovascular Medicine
• Pharmacology and Therapeutics

Background:

• Cardiovascular mortality is a significant issue in hemodialysis patients.
• Atrial fibrillation prevalence and incidence are higher in hemodialysis patients compared to the general population.
• Anticoagulation decisions in this group are complex due to unclear risk stratification and increased bleeding risk.

Purpose of the Study:

• To review the current literature on thromboembolic and bleeding events in hemodialysis patients with atrial fibrillation.
• To evaluate the impact of vitamin K antagonist (AVK) therapy in this specific patient population.
• To discuss the challenges in establishing clear indications for anticoagulation based on risk scores.

Main Methods:

• Literature review of current research on hemodialysis, atrial fibrillation, and anticoagulation.
• Analysis of studies reporting prevalence and incidence of thromboembolic and bleeding events.
• Examination of the benefit-risk balance of AVK treatment in hemodialysis subjects.

Main Results:

• Hemodialysis patients exhibit a high prevalence of both thromboembolic and bleeding events.
• The established risk scores for anticoagulation in the general population are not clearly applicable to hemodialysis patients.
• Prospective randomized studies on anticoagulant treatment benefits and risks in hemodialysis are lacking.

Conclusions:

• Anticoagulant therapy, specifically vitamin K antagonists (AVK), in hemodialysis patients with atrial fibrillation necessitates a careful balance against elevated bleeding risks.
• Individualized treatment indications are paramount, as risk stratification models are less defined compared to the general population.
• Further research, including prospective randomized trials, is needed to clarify the optimal use of anticoagulation in this vulnerable group.